SCHEMBL4907618

SCHEMBL4907618

CCCC(C)Oc1cccc(NC(=O)c2c[nH]nc2-c2cccs2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.43
KMT2A Q03164 7/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
DHODH Q02127 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HPGD P15428 4/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911760 0.92 MEN1 (0.44) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4920219 0.88 PLAU (0.46) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4918087 0.84 MET (0.42) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4915789 0.83 DHODH (0.45) MEN1KMT2AMAPTDHODHKDM4E
SCHEMBL3636752 0.82 POLB (0.35) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4922023 0.80 MEN1 (0.46) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4919177 0.75 RXFP1 (0.46) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL4916251 0.74 MAPT (0.44) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL3640392 0.74 POLB (0.36) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL4916113 0.72 RXFP1 (0.41) LMNAMAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MEN1 4628/4885KMT2A 595/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.